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Tiffany Liang 
GDF11 MEDIATES CARDIAC AND SKELETAL MUSCLE DYSFUNCTION AND 
CACHEXIA 
 
Growth differentiation factor 11 (GDF11) is important in regulating early fetal 
development of the axial skeleton and various visceral organs. Its actions on the adult 
body are less clear, and recent studies have led to conflicting accounts of GDF11’s 
ability to affect cardiac hypertrophy and skeletal muscle regeneration. If boosting GDF11 
levels in adults had the ability to rejuvenate tissues and reverse the effects of aging, then 
the therapeutic possibilities are potentially vast. We attempted to provide clarification of 
this controversial topic by studying the effects of supraphysiologic levels of GDF11 in a 
mouse model using injected Chinese hamster ovary cells producing GDF11. We found 
that increasing endogenous levels of GDF11 in this in vivo mouse model resulted in 
overall bodily wasting, specifically with evidence of cardiac and skeletal muscle atrophy. 
In light of these results, caution must be exercised if GDF11 is ever considered as a 
potential therapeutic agent. 
 
Leonidas G. Koniaris, MD, Chair  
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INTRODUCTION/BACKGROUND 
Growth differentiation factor 11 (GDF11) is a member of the transforming growth 
factor-beta superfamily of growth factors and highly homologous to myostatin/GDF8 
(Nakashima et al., 1999). GDF11 was first described in the literature as a secreted factor 
involved in tooth development (Nakashima et al., 1999), as well as axial patterning and 
renal genesis  (McPherron et al., 1999).  
More recently, work in adult mouse tissue reported a muscle regenerative 
potential for GDF11, with some describing it as “factor of youth” since it declined with 
age, and exogenous dosing was responsible for both reversing cardiac hypertrophy as 
well as improving skeletal muscle structure and function in aged animals (Andersen and 
Lim, 2014; Loffredo et al., 2013; Sinha et al., 2014). Subsequent research questioned 
these initial conclusions, with disagreements regarding the validity of the reagents and 
assays used in the experimental procedures as well as the interpretation of the results 
(Egerman et al., 2015; Poggioli et al., 2016; Rodgers and Eldridge, 2015). Additionally, 
further research into the effects of GDF11 on the hearts of aged mice did not find a 
regenerative potential, contrary to previous reports (Smith et al., 2015).  
Understanding the in vivo effects of secreted proteins remains difficult due to 
problems related to administration, bioavailability and dosing. These difficulties have 
limited the development of an understanding of the role of GDF11 in vivo and likely have 
increased the controversy surrounding its activities due to the fact that many 
experiments to date did not directly examine in vivo actions. Very successful 
determination of in vivo activities of secreted factors has been obtained utilizing cells that 
secrete active protein, as this allows sustained and high levels of in vivo expression. 
Using such an approach, we have identified in vivo effects for various other secreted 
factors including IL-6 and myostatin (Bonetto et al., 2012; Jin et al., 2007; Jin et al., 
2006; Zimmers et al., 2002; Zimmers et al., 2003). Herein, we sought to look at the 
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systemic effects of GDF11 in vivo by using a Chinese hamster ovary (CHO) cell 
overexpression model to determine in vivo effects of this controversial, but critical growth 
and differentiation factor. 
 
  3 
RESEARCH DESIGN 
Mice 
Male athymic nu/nu mice were obtained from Harlan Laboratories, Inc. 
(Indianapolis, IN, USA). For GDF11 administration, a CHO cell line stably producing 
GDF11 (CHO-GDF11) was obtained by introduction of the plasmid vector pMSXND 
containing full-length Gdf11 cDNA into DHFR-deficient CHO-DUXX cells by protoplast 
fusion and subsequent methotrexate selection. A similarly selected CHO cell line (CHO-
control) not expressing detectable recombinant protein was used as a control. 10-week 
old mice were placed under isoflurane general anesthesia using a non-rebreathing 
apparatus on a heated re-circulating waterbed, and then intramuscularly injected in the 
upper rear portion of the right hind limbs with either 5×105 CHO-GDF11 cells per mouse 
or 5×103 CHO-control cells in 0.1 mL of PBS. Total body weight was obtained daily until 
euthanasia. Tumor size was measured at intervals and at euthanasia. One mouse in the 
GDF11 group did not grow appreciable tumor, so the data obtained from this mouse was 
not included in subsequent analyses. At 10 and 13 days after CHO cell injection, 
euthanasia was performed under isoflurane anesthesia by exanguination through 
cardiac puncture followed by cervical dislocation and tissue collection. Muscles of the left 
hind limb as well as hearts were collected and weighed, then either snap frozen with 
liquid nitrogen or embedded in Tissue-Tek® OCT compound (Sakura Finetek USA, Inc., 
Torrance, CA, USA) and snap frozen in isopentane, and then stored in −80°C for later 
processing. Other organs and the carcass were also collected and weighed. Left tibia 
length was measured. All experiments were approved by and performed according to 
the guidelines of the Institutional Animal Care and Use Committees at Indiana University 
School of Medicine.  
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Echocardiography 
Cardiac muscle dimensions and function were assessed at 8, 10, and 13 days 
after CHO cell injection via echocardiography using the Vevo® 2100 system (Fujifilm 
VisualSonics Inc., Toronto, Canada). Mice were placed under isoflurane anesthesia for 
the duration of the procedure, adjusting the level to maintain a heart rate of 400 – 500 
beats per minute. Left ventricular dimensions and function were assessed by M-mode 
scanning of the left ventricular chamber. 
Electrocardiography 
Electrocardiogram (ECG) recordings were taken at 7, 9, and 13 days after CHO 
cell injection using the ECGenie apparatus (Mouse Specifics, Inc., Boston, MA, USA) as 
previously described (Mielcarek et al., 2014). Conscious mice were placed on a platform 
with footplate electrodes that captured a signal that is transduced to electrical voltage, as 
represented on the ECG recording. Several minutes of recording were obtained, and 
selected 1 – 5 second recordings of PQRST complexes were analyzed for various 
intervals using the eMouse signal analysis software (Mouse Specifics, Inc., Boston, MA, 
USA). Heart rate and heart rate variability were also obtained via this software. 
Body composition analysis 
Lean and whole body fat masses were measured at 9 and 13 days after CHO 
cell injection using EchoMRI™ (Echo Medical Systems, Houston, TX, USA). Conscious 
mice were immobilized by placement in a cylindrical apparatus, and then body 
composition was analyzed with the EchoMRI™ machine. Two measurements were 
taken per mouse per analysis and averaged to determine the final data point. 
Grip strength measurement 
Grip strength was determined at 10 and 13 days after CHO cell injection using a 
force gauge (Extech Instruments, Nashua, NH, USA). The mice were grasped at the 
base of the tail and lifted onto a metal grid. Once all four feet gripped the grid, they were 
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pulled backward by the base of the tail until they released their grip. Three 
measurements were taken in this fashion at each time point. 
Gene expression studies 
qRT-PCR was used to measure the mRNA expression levels of atrogin-1, 
MuRF1, Pax 7, Mki67, Bnip3, Bnip3L, Myh6, Myh7, Anp, and Bnp in previously snap 
frozen mouse heart and quadriceps muscle. The total RNA was extracted using the 
Qiagen miRNeasy Mini kit (Valencia, CA) according to the manufacturer’s instructions. 
The extracted RNA was quantified by NanoDrop (Thermo Scientific) at a wavelength of 
260 nm, and the RNA integrity number was measured with Agilent RNA ScreenTape 
System (Agilent Technologies). cDNA was synthesized by Thermo Scientific Verso 
cDNA synthesis kit according to manufacturer’s protocol. Primers were purchased from 
Life Technologies. qRT-PCR was conducted on a Roche LightCycler 96 Real-Time PCR 
System (Roche) using TaqMan Universal Master Mix II, with UNG (Life Technologies) in 
a 20 µl final reaction mixture. The cycling conditions were as follows: preincubation at 
95°C for 1 min and 50 cycles of 10 s at 95 °C, and 1 min at 60 °C. Experiments were 
performed in triplicate for each sample. Results were normalized to either TBP or 18S, 
and fold difference was calculated by 2−ΔΔCt. 
Western blot analysis 
Snap frozen mouse heart and quadriceps muscle were homogenized in modified 
RIPA buffer. Protein was quantified using Pierce BCA protein assay kit (Thermo 
scientific, Rockford, IL). Tissue homogenates were separated by polyacrylamide gel 
(Bio-Rad) electrophoresis under reducing conditions. Proteins from the gels were 
electrophoretically transferred to Nitrocellulose membranes (Bio-Rad). Immunoblotting 
was performed using the following antibodies: LC3B (Sigma, Saint Louis, MO); p62 (BD 
Transduction Laboratories); pSMAD2, SMAD2, pAKT, AKT, pFOXO3a, FOXO3a, p4E-
BP1 70, p4E-BP1 65, p4E-BP1 37/46, 4E-BP1, ubiquitin, and GAPDH (Cell Signaling 
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Technology). Antibody binding was detected following appropriate secondary antibody 
methods using SuperSignal West Femto (Thermo Scientific) or Odyssey CLx western 
blot detection system (Li-Cor, Lincoln, NE). Protein quantification was performed with 
ImageJ (NIH, Bethesda, MD, USA). 
Histology and immunofluorescence 
Hearts were snap frozen in isopentane cooled in liquid nitrogen immediately after 
sacrifice for histological analyses. Hearts were cut into 7 µm sections on a cryostat and 
mounted onto glass slides (Superfrost™ Plus Microscope Slides; Fisher Scientific), and 
stained with hematoxylin and eosin using standard procedures. Quantification of 
cardiomyocyte cross-sectional area (CSA) was measured manually using ImageJ (NIH, 
Bethesda, MD, USA). Measurements were obtained from ten, non-overlapping 20X 
fields from each cross-section per animal in each treatment group. A mean was then 
calculated for each animal from the CSA measurements recorded.  
The tibialis muscle was excised immediately after sacrifice and snap frozen in 
isopentane cooled in liquid nitrogen. The tibialis was cut into 10 µm sections on a 
cryostat and mounted onto glass slides (Superfrost™ Plus Microscope Slides; Fisher 
Scientific). Tibialis sections were post-fixed in 4% paraformaldehyde (Affymetrix; Santa 
Clara, CA). Sections were blocked in 8% bovine serum albumin and reacted with an 
anti-dystrophin antibody (1:400, Vector Laboratories; Burlingame, CA) overnight at 4° C. 
Sections were washed and incubated with a fluorescent secondary antibody (1:1000, 
Alexa Fluor® 594; Fisher Scientific) for one hour at room temperature. Slide cover glass 
was mounted using aqueous mounting media. Sections were visualized using a 
fluorescent camera on an Observer.Z1 system (Zeiss; Oberkochen, Germany) and 
measurements were obtained from ten, non-overlapping 10X fields from each cross-
section per animal in each treatment group using an Image J macro (Minamoto et al., 
2007). Means were calculated from total CSA measurements for each individual animal.   
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Statistical analyses 
Unpaired t-test or one-way analysis of variance with multiple comparisons were 
used to detect statistical significance with GraphPad Prism version 6.07 for Windows, 
GraphPad Software, La Jolla California USA, www.graphpad.com. 
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RESULTS 
Overall Body Weight and Composition Decrease with GDF11 Overexpression 
We first sought to characterize the global effects of GDF11 overexpression in 
adult male mice. Mice were divided into three groups – a normal group where no cells 
were injected, a control group where CHO cells expressing no recombinant protein were 
injected, and an experimental group where CHO cells overexpressing GDF11 were 
injected into the right hind limb. At day 10 after injection, the body weights of the GDF11 
mice were significantly reduced compared to the control mice; this difference was even 
greater at day 13 (Figure 1A). A significant decrease in whole body lean mass as 
measured by EchoMRI™, however, was not seen until day 13, whereas there was no 
difference in whole body fat mass measured by EchoMRI™, between the groups (Figure 
1B). Regardless, dramatic size differences in gross anatomy were seen at day 15 
(Figures 1C and 1D). At necropsy, weights of various organs, such as the heart (Figures 
1D, 2A and 2B), skeletal muscle (Figures 5A, 5B, and 5C), epididymal fat pad, kidney, 
and liver, as well as the carcasses (Figure S1) of the GDF11 mice were significantly 
decreased at day 13. 
Heart Weight and Cardiomyocyte Size Decrease with GDF11 Overexpression 
There are conflicting prior reports on the effect of GDF11 administration on 
mouse heart and cardiomyocyte size (Loffredo et al., 2013; Poggioli et al., 2016; Smith 
et al., 2015). Our studies using overexpression of GDF11 in mice showed that heart 
weight and cardiomyocyte size decreased significantly compared to controls by day 13 
of GDF11 exposure, consistent with the Loffredo and Poggioli studies. Heart weights 
when normalized using both initial body weight (Figure 2A) and tibia length (Figure 2B) 
yielded similar results. The GDF11 group showed a significant weight reduction in 
cardiac mass by day 10 that was even more apparent by day 13. Mean cardiomyocyte 
cross-sectional area of the GDF11 group was significantly smaller than controls at day 
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13 (Figure 2C). Correspondingly, the frequency distribution of these area measurements 
demonstrated a left shift in the GDF11 group size distribution compared to controls 
(Figure 2D). Fresh mouse hearts and hematoxylin and eosin staining of histologic cross-
sections of the heart through the left and right ventricles demonstrate visibly smaller 
heart and cardiomyocyte size in the GDF11 group (Figure 2E). 
Gene Markers in Hearts of Mice with GDF11 Overexpression Indicate Muscle Atrophy 
In addition to morphologic changes, the gene expression profile of hearts 
exposed to GDF11 differed from controls. In particular, the gene expression of ubiquitin-
protein ligases atrogin-1, also known as muscle atrophy F-box (MAFbx), and MuRF1 
(Bodine et al., 2001; Gomes et al., 2001) was increased at days 10 and 13, although the 
increase in atrogin-1/MAFbx at day 13 did not reach statistical significance (Figure 2F). 
Moreover, there was evidence of diminished cellular proliferation with the decreased 
expression of Mki67 and autophagy with the increased expression of Bnip3 in the 
GDF11 mice at day 13. Differences in Bnip3L expression were not statistically significant 
following GDF11 exposure (Figure 2F). This expression profile suggests activation of 
muscle atrophy pathways. 
Expression of gene markers of cardiac dysfunction was generally unchanged 
with GDF11 overexpression compared to controls. Similar to results from a recent study 
examining the effects of GDF11 on mouse hearts (Smith et al., 2015), we did not find 
any statistically significant changes in the expression of Anp, Myh6 (αMHC), or Myh7 
(βMHC) in the GDF11 group. While expression of Bnp at day 10 was significantly 
increased in the GDF11 group compared to control, the difference at day 13 did not 
reach statistical significance (Figure 2F).  
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Echocardiography in Mice with GDF11 Overexpression Demonstrates Reduced Cardiac 
Size and Function 
Echocardiographic studies supported our findings that the hearts of mice with 
GDF11 overexpression are reduced in size compared to controls and further 
demonstrated a reduction in function. Parasternal long and short axis views captured in 
brightness mode (B-mode) ultrasound on day 13 after injection demonstrate that the 
GDF11 mice have decreased left ventricular size compared to controls (Figures 3A and 
3B). Motion mode (M-mode) images on day 13 (Figure 3C) were used to measure 
cardiac dimensions and calculate functional assessments (Figure 4). Cardiac size and 
dimensions were generally decreased in the GDF11 group, where significant decreases 
in left ventricular internal diameter during diastole, posterior wall thickness during 
systole, and left ventricular mass were apparent by day 10, then later in posterior wall 
thickness during diastole by day 13 (Figures 4A, 4B, and 4C). GDF11 overexpression 
also significantly decreased stroke volume (Figure 4D), ejection fraction (Figure 4E), and 
fractional shortening (Figure 4F) by day 10, compared to control. The echocardiographic 
measurements of normal and control mice were generally similar, other than an 
unexplained increase in left ventricular internal diameter in the control mice by day 10 
(Figure S2). 
Electrocardiography was also performed to further characterize cardiac rate and 
conductivity following GDF11 exposure; no appreciable differences were observed either 
when compared to normal or control mice (Figure S3). 
Regulatory Pathways in Hearts of Mice with GDF11 Overexpression Demonstrate 
Increased Degradation of Cardiac Muscle 
Western blot analyses of cardiac muscle were performed to detect levels of 
various mediators in muscle metabolic pathways. GDF11 overexpression increased 
SMAD2 by day 13. Phosphorylated SMAD2 appeared increased but this did not reach 
  11 
statistical significance following GDF11 exposure (Figure 5A). Ubiquitin levels were 
increased in GDF11 mice compared to the control group (Figure 5B). There were no 
statistically significant differences detected in levels of pFOXO3a, FOXO3a, p4E-BP1, 
and p62 (Figure S4). 
Skeletal Muscle Mass Decreases with GDF11 Overexpression 
To examine the effects of GDF11 overexpression on mouse skeletal muscle, we 
first measured the weights of the left hind limb gastrocnemius, quadriceps, and tibialis 
muscles. By day 13 after injection with CHO-GDF11 cells, muscle mass was significantly 
decreased compared to control (Figures 6A, 6B, and 6C). Consistent with this finding, 
grip strength in the GDF11 mice was also significantly decreased at day 13 (Figure 6D), 
although a recent study showed improved exercise endurance and grip strength in 33- to 
39-month old mice treated with recombinant GDF11 (Sinha et al., 2014). It is interesting 
to note, however, that myocyte fiber size did not differ significantly between the groups 
(Figures 6E and 6F). Laminin staining of tibialis muscle cross-sections show myocyte 
size and shape (Figure 6G). 
Gene Markers in Quadriceps of Mice with GDF11 Overexpression Demonstrate Muscle 
Atrophy 
Similar to the GDF11 mouse hearts, the quadriceps of GDF11 mice also 
indicated a pattern of muscle atrophy. There was significantly increased expression of 
atrogin-1 and MuRF1 by day 13 compared to controls (Figure 6H). Mki67 expression 
was significantly decreased and Bnip3 expression trended towards being increased in 
the GDF11 group, although there did not appear to be a difference in Bnip3L expression 
(Figure 6H). Pax7 expression in the muscle was unchanged between GDF11 mice and 
controls, however, suggesting that GDF11 may not affect muscle regenerative 
processes differently than controls (Figure 6H).  
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Increased Degradation and Decreased Synthesis of Skeletal Muscle in Quadriceps of 
Mice with GDF11 Overexpression  
Western blot analyses were also performed on mouse quadriceps. Increased 
levels of pSMAD2 indicate activation of the GDF11 signaling pathway in mice with 
GDF11 overexpression. SMAD2 levels were unchanged between GDF11 mice and 
control, and there was a decrease compared to normal mice (Figure 7A). Levels of 
mediators of the hypertrophy/atrophy pathway, AKT and FOXO3a, were unchanged with 
GDF11 overexpression (Figure 7B). FOXO1 was undetected on Western blot. However, 
GDF11 did affect translational regulation of protein synthesis. Phosphorylated 4E-BP1 
levels were decreased in GDF11 mice while 4E-BP1 levels were increased, indicating 
decreased synthesis of protein in the quadriceps muscle (Figure 7C). Furthermore, 
increased levels of autophagy markers LC3-II, LC3-II/LC3-I, and p62 (Figure 7D) as well 
as increased ubiquitin levels (Figure 7E) indicated increased degradation of the skeletal 
muscle. 
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CONCLUSION 
Our results show that GDF11 overexpression in adult mice leads to cachexia, 
with consequential cardiac and skeletal muscle dysfunction and weakness. These 
results are not surprising, as myostatin is 90% homologous to GDF11 and known to be 
an important player in cachexia (Zimmers et al., 2002). Initial studies (Loffredo et al., 
2013; Sinha et al., 2014) showed that GDF11 declines with age, and that the 
reintroduction of this “factor of youth” (Andersen and Lim, 2014) reverses age-related 
degenerative changes in the body, such as cardiac hypertrophy and skeletal muscle 
dysfunction/atrophy (Loffredo et al., 2013; Poggioli et al., 2016; Sinha et al., 2014). In in 
vivo experiments detailed by Smith et al’s recent publication, however, they saw no 
changes in cardiac structure or function with GDF11 administration (Smith et al., 2015). 
Based on our results, we believe that the previous finding of cardiac hypertrophy 
reversal with GDF11 administration is not actually a reversion to normal cardiac muscle, 
but rather atrophy to dysfunctional muscle seen in cachexia. Similarly, we also find that 
GDF11 overexpression leads to skeletal muscle cachexia. 
There are conflicting research findings on body composition changes after 
GDF11 administration. Poggioli et al’s study briefly mentioned observing weight loss in 
both young and old mice that were given certain doses of exogenous GDF11 (0.5 
mg/kg/day and/or 1 mg/kg/day), but this finding was not explored in more detail (Poggioli 
et al., 2016). At the 0.1 mg/kg/day dosage in Sinha and Jang et al’s study, body weight 
and muscle mass (tibialis and extensor digitorum longus) were shown to be unchanged 
in both young and old mice in (Sinha et al., 2014). We find that after 13 days of 
overexpression of GDF11 via CHO cell tumors, body weight decreased dramatically 
compared to controls, largely contributed by the loss in lean mass. Muscle mass, as 
measured from the gastrocnemius, quadriceps, and tibialis muscles, also significantly 
decreased with GDF11 overexpression. The differences in body weight and muscle 
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mass changes between our study and that of Sinha and Jang et al could potentially be 
attributed to differences in circulating GDF11 levels.  
There have also been conflicting findings on changes in the heart with GDF11 
administration. In the Loffredo et al study, intraperitoneal GDF11 administration resulted 
in decreased heart weight and decreased cardiomyocyte fiber size, but no difference in 
echocardiography compared to controls (Loffredo et al., 2013). Similarly, Poggioli et al 
showed that for both young and old mice, intraperitoneal GDF11 administration 
decreased heart weight as well as cross-sectional area of cardiomyocytes (Poggioli et 
al., 2016). However, in the Smith et al study, intraperitoneal GDF11 administration in 24 
month old mice resulted in no differences in heart weight, echocardiography, terminal 
hemodynamic studies, cardiomyocyte cross-sectional area, or amount of fibrosis 
compared to controls (Smith et al., 2015). Our study supports that GDF11 actually 
promotes cardiac atrophy with corresponding decreases in both heart size and function. 
It is interesting to note, however, that a study by Usui et al reported that atrogin-1 
mediates cardiac hypertrophy (Usui et al., 2011), contrary to our findings.  
In one study of failing hearts (presumably with a hypertrophic component), the 
investigators found that ANP levels are greater while αMHC and βMHC levels are 
decreased compared to non-failing hearts (Razeghi et al., 2001). In another study, 
however, cardiac hypertrophy due to pressure overload was found to increase both 
αMHC and βMHC levels in cardiomyocytes (Lopez et al., 2011). While these studies 
differed in the direction of change in the cardiac markers, they nevertheless 
demonstrated that the levels of cardiac markers are changed by hypertrophic cardiac 
pathology. In accordance with one of the recent GDF11 studies (Smith et al., 2015), we 
also found no differences in levels of cardiac markers (ANP, BNP, αMHC, and βMHC) 
that would suggest pathologic hypertrophy. These findings further support that the 
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atrophic effects of GDF11 likely do not act by diminishing pathologic cardiac 
hypertrophy. 
Regarding skeletal muscle regenerative potential, Sinha and Jang et al showed 
that GDF11 supplementation in old mice increased the frequency and function of 
satellite cells as well as improved exercise endurance and grip strength (Sinha et al., 
2014). Conversely, Egerman et al showed that GDF11 treatment did not affect 
regenerative capacity or cross-sectional area of skeletal muscle after injury; in fact, in 
vitro studies showed that GDF11 actually decreased the growth of adult and aged 
satellite cells and did not change the expression of markers of muscle differentiation 
(Egerman et al., 2015). Our studies show that GDF11 overexpression resulted in 
activation of muscle atrophy pathways, with indications of increased degradation and 
decreased synthesis of skeletal muscle proteins. Accordingly, the grip strength 
measurements in our study demonstrated significantly decreased function in GDF11 
mice, although we did not study the effects in old mice using our model of CHO cell 
overexpression. It therefore seems highly unlikely that any regenerative activity seen 
with satellite cell activation, if present, would result in improved muscle function. In fact, 
our study shows 20-30% decreases in skeletal muscle mass with GDF11 
overexpression while mean cross-sectional area of myocytes is unchanged compared to 
controls. One possible explanation to these findings is that skeletal myocyte fibers in the 
GDF11 mice are dying even though the surviving fibers are maintaining their cross-
sectional areas, suggesting lack of regenerative potential. 
While this study provides another piece of evidence to the GDF11 story, it has its 
limitations. Unlike other recent in vivo investigations of exogenous GDF11 administration 
in mice, our study used only 10-week old (young) mice. We therefore did not examine 
the effects of GDF11 overexpression in aged mice (e.g. 24-month old) compared to 
young mice and cannot say with certainty that our results will also translate with age and 
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its accompanying physiologic changes. The focus of this study, however, was not so 
much on how GDF11 overexpression differs with age, but rather on better defining its 
effects on cardiac and skeletal muscle. Certainly, future studies may be warranted to 
explore what role, if any, that age plays in changing the pattern of cachexia in those with 
supraphysiologic levels of GDF11. 
This study also did not quantify the exact levels of circulating GDF11 for each 
mouse. However, we assumed that there were similar amounts of GDF11 expressed 
and circulating in each experimental mouse, since the same numbers of CHO-GDF11 
cells were injected per mouse. We also closely monitored the size of the tumors that 
grew in the CHO-injected mice, and we discarded the data from an outlier mouse from 
the GDF11 group that did not have adequate, similar-sized tumor growth compared to 
the other mice in the same group. Furthermore, we documented induction of GDF11 
signaling in the GDF11 mice, observing that phosphorylated SMAD2 levels were 
increased compared to normal and control mice. Because this study used an 
overexpression model, however, we were unable to examine the effects of GDF11 at 
differing lower levels. 
We conclude that GDF11 overexpression in adult mice causes significant weight 
loss and cachexia, specifically causing cardiac and skeletal muscle dysfunction and 
weakness. Any endeavors to utilize GDF11 as a therapeutic agent should be 
approached with caution. 
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FIGURE 1 
Overall Body Weight and Composition Decrease with GDF11 Overexpression 
(A) Final body weights of normal, control, and GDF11 mice at sacrifice, reported as 
percentages of initial body weight (IBW). Final body weights of normal mice (n=4) taken 
at day 13 are shown to the left of the dashed vertical line, and those of control and 
GDF11 mice at day 10 (n=5 and n=8, respectively) and at day 13 (n=5 and n=7, 
respectively) are compared to the right of the line. Horizontal lines with error bars 
indicate mean ± SEM. Statistically significant differences are indicated at p < 0.01 (**) 
and p < 0.0001 (****). 
(B) Fat mass (left panel) and lean mass (right panel) as measured by EchoMRI™ body 
composition analysis for normal, control, and GDF11 mice at days 9 and 13. Horizontal 
lines with error bars indicate mean ± SEM. Statistically significant differences are 
indicated at p < 0.0001 (****). 
(C) Control (left) and GDF11 (right) mice at sacrifice, juxtaposed to illustrate significant 
weight loss in GDF11 mice at day 15. 
(D) Organs at necropsy in normal, control, and GDF11 mice at day 15. H, heart; K, 
kidneys; G, gastrocnemius; T, tibialis; Q, quadriceps; S, spleen; L, liver. 
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FIGURE 2 
Heart and Cardiomyocyte Size Decrease with GDF11 Overexpression 
(A and B) Heart weights (HW) of normal, control, and GDF11 mice at sacrifice, reported 
as (A) percentages of initial body weight (IBW) and (B) normalized to tibia length (TL). 
Heart weights of normal mice (n=4) taken at day 13 are shown to the left of the dashed 
vertical line, and those of control and GDF11 mice at day 10 (n=5 and n=8, respectively) 
and at day 13 (n=5 and n=7, respectively) are compared to the right of the line. 
Horizontal lines with error bars indicate mean ± SEM. Statistically significant differences 
are indicated at p < 0.01 (**) and p < 0.001 (***). 
(C) Mean cardiomyocyte fiber cross-sectional area (CSA) of normal, control, and GDF11 
mice at day 13. Data are mean ± SD. Statistically significant differences are indicated at 
p < 0.0001 (****). 
(D) Histogram of cardiomyocyte CSA for normal, control, and GDF11 mice at day 13. 
Numerical data of mean cardiomyocyte CSA (data are mean ± SEM) and number of 
fibers measured are shown in table on right. 
(E) Gross anatomy (top row of figure on left, 5 mm scale bar) and hematoxylin and eosin 
staining (cross-section, middle row, 3 mm scale bar; 40x magnification, bottom row) of 
normal, control, and GDF11 mouse hearts at day 13. LV, left ventricle; RV, right 
ventricle. 
(F) Gene expression analyses of cardiac muscle in normal (left of dashed vertical line, 
measured at day 13), control, and GDF11 mice at days 10 and 13. Data are represented 
as mean fold change ± SD. Fold change for atrogin-1 and MuRF1 were calculated using 
reference gene TBP, while data for all other genes were calculated using reference gene 
18S. Statistically significant differences are indicated at p < 0.05 (*), p < 0.001 (***) and p 
< 0.0001 (****). 
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FIGURE 3 
Echocardiographic Images in Mice with GDF11 Overexpression Demonstrate 
Reduced Cardiac Size and Function 
(A and B) Brightness mode image views of control and GDF11 mouse hearts in the 
parasternal (A) long axis view of the left ventricle (outlined in gray) during systole and 
diastole and the (B) short axis view of the left ventricle at the papillary muscle level 
during systole, taken at day 13. AW, anterior wall; LV, left ventricle; PM, papillary 
muscle; PW, posterior wall. White scale bars on bottom left corner, 1 mm. 
(C) Motion mode imaging of control and GDF11 mouse hearts for left ventricular wall, 
chamber, and cardiac function measurements at day 13. LVIDd/s, left ventricular internal 
diameter (diastole/systole); PW, posterior wall. 
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FIGURE 4 
Echocardiographic Measurements in Mice with GDF11 Overexpression 
Demonstrate Reduced Cardiac Size and Function 
(A and B) Time course of echocardiographic dimension changes in control and GDF11 
mice. (A) Left ventricular internal diameter (diastole/systole) (LVIDd/s) and (B) posterior 
wall thickness (diastole/systole) (PWTd/s) measurements are shown. 
(C-F) Time course of changes in echocardiographic measurements of (C) left ventricle 
(LV) mass and cardiac function as measured by (D) stroke volume, (E) ejection fraction, 
and (F) fractional shortening. Horizontal lines with error bars indicate mean ± SD. 
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**), and p < 
0.001 (***). 
  
  24 
2 .5
3 .0
3 .5
4 .0
4 .5
5 .0
5 .5
m
m
L V ID d L V ID s L V ID d L V ID s L V ID d L V ID s
**
*
D a y  8 D a y  1 0 D a y  1 3
C o n tro l
G D F 1 1
-5 %
-7 %
0 .4
0 .6
0 .8
1 .0
1 .2
1 .4
m
m
D a y  8 D a y  1 0 D a y  1 3
P W T d P W T s P W T d P W T s P W T d P W T s
**
*
**
C o n tro l
G D F 1 1
-1 4 %
-1 8 %
-2 7 %
3 0
5 0
7 0
9 0
1 1 0
L
V
 m
a
ss
 (
m
g
)
D a y  8 D a y  1 0 D a y  1 3
**
***
C o n tro l
G D F 1 1
-1 5 %
-2 9 %
0
2 0
4 0
6 0
8 0
S
tr
o
ke
 V
o
lu
m
e
 (
m
l)
D a y  8 D a y  1 0 D a y  1 3
***
**
C o n tro l
G D F 1 1
-2 5 %
-3 7 %
1 0
2 0
3 0
4 0
5 0
6 0
7 0
E
je
ct
io
n
 F
ra
ct
io
n
 (
%
)
D a y  8 D a y  1 0 D a y  1 3
*
C o n tro l
G D F 1 1
*
-1 7 %
-2 5 %
0
1 0
2 0
3 0
4 0
F
ra
ct
io
n
a
l S
h
o
rt
e
n
in
g
 (
%
)
*
D a y  8 D a y  1 0 D a y  1 3
C o n tro l
G D F 1 1
**
-1 9 %
-2 8 %
  
A 
 
B 
 
C 
 
E 
 
D 
 
F 
 
  25 
0 .0
0 .5
1 .0
1 .5
2 .0
N
o
rm
a
liz
e
d
 t
o
G
A
P
D
H
U b iq u it in
*
N o rm a l
C o n tro l
G D F 1 1
+ 4 2 %
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
N
o
rm
a
liz
e
d
 t
o
G
A
P
D
H
p S M A D 2 S M A D 2
N o rm a l
C o n tro l
G D F 1 1
*
+ 1 4 5 %
FIGURE 5 
Protein Regulatory Pathways in Hearts of Mice with GDF11 Overexpression 
Demonstrate Increased Degradation 
(A and B) Western blotting analyses to determine (A) activation of SMAD2 signaling and 
(B) ubiquitination levels in normal, control, and GDF11 mice at day 13. Blots are 
presented on the top and protein levels quantified in graphs on the bottom. Horizontal 
lines with error bars indicate mean ± SD. Statistically significant differences are indicated 
at p < 0.05 (*). 
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FIGURE 6 
Skeletal Muscle Weight and Function Decrease with GDF11 Overexpression 
(A-C) Weights of the left hind limb (A) gastrocnemius, (B) quadriceps, and (C) tibialis 
muscles taken at sacrifice were reported as percentages of initial body weight (IBW). 
Muscle weights of normal mice (n=4) taken at day 13 are shown to the left of the dashed 
vertical line, and those of control and GDF11 mice at day 10 (n=5 and n=8, respectively) 
and at day 13 (n=5 and n=7, respectively) are compared to the right of the line. 
Horizontal lines with error bars indicate mean ± SEM. Statistically significant differences 
are indicated at p < 0.05 (*), p < 0.01 (**), and p < 0.0001 (****). 
(D) Grip strength measurements at day 10 and 13. Each data point is an average of 3 
separate measurements in each mouse. Horizontal lines with error bars indicate mean ± 
SEM. Statistically significant differences are indicated at p < 0.05 (*). 
(E) Mean quadriceps myocyte fiber cross-sectional area (CSA) of normal, control, and 
GDF11 mice at day 13. Data are mean ± SEM. 
(F) Histogram of quadriceps CSA for normal, control, and GDF11 mice at day 13. 
(G) Laminin staining (10x magnification, 100 µm scale bar) of left hind limb quadriceps 
muscle cross-sections in normal, control, and GDF11 mice at day 13. Numerical data of 
mean myocyte CSA (data are mean ± SEM) and number of fibers measured are shown 
in table below. 
(H) Gene expression analyses of quadriceps muscle in normal (left of dashed vertical 
line, measured at day 13), control, and GDF11 mice at days 10 and 13. Data are 
represented as mean fold change ± SD. All fold changes calculated using reference 
gene 18S. Statistically significant differences are indicated at p < 0.05 (*) and p < 0.001 
(***). 
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FIGURE 7 
Protein Regulatory Pathways in Quadriceps of Mice with GDF11 Overexpression 
Demonstrate Increased Degradation and Decreased Synthesis 
(A-E) Western blotting analyses to determine activation of (A) SMAD2 signaling, (B) 
hypertrophy/atrophy pathways (arrowhead points to FOXO3a), (C) protein translation 
and synthesis, (D) autophagy, and (E) ubiquitination in normal, control, and GDF11 mice 
at day 13. Blots are presented on the top and protein levels quantified in graphs on the 
bottom. Horizontal lines with error bars indicate mean ± SD. Statistically significant 
differences are indicated at p < 0.05 (*), p < 0.01 (**), and p < 0.0001 (****). 
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FIGURE S1 
Reduced Organ Weights in Mice with GDF11 Overexpression 
(A-F) Weights of (A) carcasses and (B-F) various organs at sacrifice, reported as 
percentages of initial body weight (IBW). Final body weights of normal mice (n=4) taken 
at day 13 are shown to the left of the dashed vertical line, and those of control and 
GDF11 mice at day 10 (n=5 and n=8, respectively) and at day 13 (n=5 and n=7, 
respectively) are compared to the right of the line. Horizontal lines with error bars 
indicate mean ± SEM. Statistically significant differences are indicated at p < 0.05 (*), p 
< 0.001 (***), and p < 0.0001 (****). 
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FIGURE S2 
Echocardiography in Normal and Control Mice are Similar  
(A and B) Time course of echocardiographic dimension changes in normal and control 
mice. (A) Left ventricular internal diameter (diastole/systole) (LVIDd/s) and (B) posterior 
wall thickness (diastole/systole) (PWTd/s) measurements are shown. 
(C-F) Time course of changes in echocardiographic measurements of (C) left ventricle 
(LV) mass and cardiac function as measured by (D) stroke volume, (E) ejection fraction, 
and (F) fractional shortening. Horizontal lines with error bars indicate mean ± SD. 
Statistically significant differences are indicated at p < 0.05 (*) and p < 0.01 (**). 
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FIGURE S3 
Electrocardiography is Unchanged in Mice with GDF11 Overexpression 
(A-I) Time course of electrocardiographic measurements of normal (n=4), control (n=10, 
days 7 and 9; n=5, day 13), and GDF11 (n=16, days 7 and 9; n=8, day 13) mice. Data 
points represent mean ± SD. Statistically significant difference is indicated at p < 0.05 
(*). 
6 0 0
6 5 0
7 0 0
7 5 0
8 0 0
8 5 0
9 0 0
D a y
H
e
a
rt
 r
a
te
 (
b
p
m
)
7 9 1 3
0
1 0
2 0
3 0
4 0
D a y
H
R
V
 (
b
p
m
)
7 9 1 3
1 0
1 5
2 0
2 5
D a y
P
Q
 (
m
s)
7 9 1 3
1 5
2 0
2 5
3 0
3 5
D a y
P
R
 (
m
s)
7 9 1 3
*
7
8
9
1 0
1 1
1 2
1 3
D a y
Q
R
S
 (
m
s)
7 9 1 3
3 0
3 5
4 0
4 5
5 0
D a y
Q
T
 (
m
s)
7 9 1 3
3 5
4 0
4 5
5 0
5 5
D a y
Q
T
c 
(m
s)
N o rm a l C o n tro l G D F 1 1
7 9 1 3
6 0
7 0
8 0
9 0
1 0 0
D a y
R
R
 (
m
s)
7 9 1 3
2 5
3 0
3 5
4 0
D a y
S
T
 (
m
s)
7 9 1 3
  
A B C 
D E F 
G H I 
  35 
0 .0
0 .5
1 .0
1 .5
2 .0
N
o
rm
a
liz
e
d
 t
o
G
A
P
D
H
p F O X O 3 a F O X O 3 a
N o rm a l
C o n tro l
G D F 1 1
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
N
o
rm
a
liz
e
d
 t
o
G
A
P
D
H
p 4 E -B P 1  3 7 /4 6
N o rm a l
C o n tro l
G D F 1 1
0 .0
0 .5
1 .0
1 .5
2 .0
N
o
rm
a
liz
e
d
 t
o
G
A
P
D
H
p 6 2
N o rm a l
C o n tro l
G D F 1 1
FIGURE S4 
Protein Expression in Hearts of Mice with GDF11 Overexpression 
(A-C) Western blotting analyses to determine activation of (A) hypertrophy/atrophy 
pathways, (B) protein translation and synthesis, and (C) autophagy in normal, control, 
and GDF11 mice at day 13. Blots are presented on the top and protein levels quantified 
in graphs on the bottom. Horizontal lines with error bars indicate mean ± SD. 
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